Kuvan (Sapropterin Dihydrochloride) Patent Expiration, LOE Window & CMS Spending
Kuvan (Sapropterin Dihydrochloride) by BioMarin Pharmaceutical: FDA Orange Book LOE 2026-05-16, 5 AB generics, $24.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | BioMarin Pharmaceutical |
| FDA Application & Pathway | N022181 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-05-16 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $24.5M |
| 2024 Medicare Part D Spend | $3.5M |
| 2024 Medicaid Spend | $21.0M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.